A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of fazirsiran in the treatment

A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of fazirsiran in the treatment of Alpha-1 Antitrypsin deficiency–dssociated liver disease with METAVIR stage F2 to F4 fribrosis.

Obert

Codi protocol: TAK-999-3001
Codi EudraCT: _
Grup de recerca: Malalties Hepàtiques
Servei: Hepatologia
Investigador/a principal: Pons Delgado, Mònica
Malaltia: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III
Estat: Reclutant voluntaris